New research data surrounding this compound, specifically the 120mg formulation branded as ZPHC, indicate a considerable benefit on physique loss and linked chronic illnesses . Researchers posit that this dual acting , influencing both GLP-1 and GIP pathways , may offer a noteworthy advance in the approach of overweight and associated disease risk